As a fraught, divisive, and violent election came to an end, it was too close to call whether it would be Vice President Kamala Harris or former President Donald Trump until the dark, predawn hours ...
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -3.54% and 4%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ...